research IL-36γ Drives Skin Toxicity Induced by EGFR/MEK Inhibition and Commensal Cutibacterium Acnes
A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.
Search
for
Sort by
Research
90-120 / 751 results
research The Management of EGFR Inhibitor Adverse Events: A Case Series and Treatment Paradigm
Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
research EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
research Rash from EGFR Inhibitors: Opportunities and Challenges for Palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research EGFR Controls Hair Shaft Differentiation in a p53-Independent Manner
EGFR helps control how hair grows and forms without needing p53 protein.
research Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
Blocking EGFR in skin cells doesn't majorly increase inflammation markers.
research EGFR Marks a Subpopulation of Dermal Mesenchymal Cells Highly Expressing IGF1 Which Enhances Hair Follicle Regeneration
A certain type of skin cell, marked by EGFR, produces a lot of IGF1 and helps hair follicles grow back faster.
research Scarring Hair Follicle Destruction Is Driven by the Collapse of EGFR-Protected JAK-STAT1-Sensitive Stem Cell Immune Privilege
A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
research Single-Cell Transcriptomic Profile of EGFR-Deficient Epidermal Compartments During Folliculitis
EGFR deficiency causes significant changes in skin cells and hair follicles.
research Epidermal Keratinocytes Regulate Bacterial Immune Responses and Host Defense Through EGFR
EGFR inhibitors cause skin issues and hair loss by weakening skin defenses, suggesting antibiotics and targeted treatments can help.
research Scarring Alopecia Is Driven by the Collapse of EGFR-Protected JAK-STAT1-Sensitive Stem Cell Immune Privilege
Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
research Folliculitis Decalvans-Like Alopecia During EGFR Inhibitors Treatment for Lung Cancer: A Case Series of 6 Patients
Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.
research Y27632 Promotes Proliferation via EGFR Signaling in a Newly Isolated and Characterized Human Primary Sebocyte Cell Line
Y27632 increases cell growth through EGFR signaling, not ROCK1/2.
research Mario Lacouture: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
Dr. Mario Lacouture recommends preventive and specific treatments for skin side effects caused by EGFR inhibitors to improve patients' quality of life.
research Targeted Inhibition of EGFR Reduces Anti-Microbial Defense Mechanisms at the Hair Canal
research Molecular Docking Studies and ADME Prediction of Novel Isatin Analogs with Potent Anti-EGFR Activity
Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.
research Genetically Null Mice Reveal a Central Role for Epidermal Growth Factor Receptor in the Differentiation of the Hair Follicle and Normal Hair Development
EGFR is essential for normal hair development and follicle differentiation.
research The PRIDE Syndrome: Dermatological Side Effects of EGFR Inhibitors
PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.
research Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
research The Incidence and Management of Cutaneous Adverse Events of the Epidermal Growth Factor Receptor Inhibitors
EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.
research Perifollicular Xanthomas Associated With Epidermal Growth Factor Receptor Inhibitor Therapy
EGFR inhibitors can cause yellowish skin eruptions.
research The Epidermal Growth Factor Receptor Decreases Stathmin 1 and Triggers Catagen Entry in the Mouse
EGFR helps mouse hair follicles stop growing by reducing certain growth regulators.
research Successful Treatment of Epidermal Growth Factor Receptor Inhibitor-Induced Alopecia with Doxycycline
Doxycycline can effectively treat hair loss caused by EGFR inhibitors.
research Arrow Sign: A Rapid Microscopic Diagnosis of Hair Change Associated with Epidermal Growth Factor Receptor Inhibitors
A new method quickly detects hair changes from EGFR inhibitors using a microscope.
research Association Between EGF and EGFR Gene Polymorphisms and Susceptibility to Alopecia Areata in the Korean Population
Certain gene variations in EGF and EGFR may increase the risk of alopecia areata in Koreans.
research Epidermal Growth Factor Receptor Inhibitor-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema: Should You Discontinue the Offending Agent?
You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.
research Epidermal Growth Factor Receptor Protects From Immune Privilege Collapse and Scarring Hair Follicle Destruction
Blocking EGFR can lead to hair loss due to inflammation and stem cell damage.
research Epidermal Growth Factor Receptor as a Key Regulator of Immune Privilege
EGFR is crucial for preventing hair follicle inflammation and hair loss.
research Salt-Losing Tubulopathy and Chronic Dermatitis
Genetic testing for EGFR mutations is crucial in similar cases.
research Comparison of Pemetrexed and Docetaxel as Salvage Chemotherapy for the Treatment of Non-Small-Cell Lung Cancer After the Failure of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.